Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neuronetics (STIM) EBT Margin (2017 - 2025)

Historic EBT Margin for Neuronetics (STIM) over the last 9 years, with Q3 2025 value amounting to 25.54%.

  • Neuronetics' EBT Margin rose 254700.0% to 25.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.2%, marking a year-over-year increase of 127900.0%. This contributed to the annual value of 55.88% for FY2024, which is 54500.0% down from last year.
  • According to the latest figures from Q3 2025, Neuronetics' EBT Margin is 25.54%, which was up 254700.0% from 26.31% recorded in Q2 2025.
  • Neuronetics' 5-year EBT Margin high stood at 25.54% for Q3 2025, and its period low was 78.37% during Q1 2022.
  • Its 5-year average for EBT Margin is 52.51%, with a median of 53.08% in 2021.
  • Within the past 5 years, the most significant YoY rise in Neuronetics' EBT Margin was 393600bps (2021), while the steepest drop was -317200bps (2021).
  • Quarter analysis of 5 years shows Neuronetics' EBT Margin stood at 53.08% in 2021, then grew by 7bps to 49.12% in 2022, then skyrocketed by 37bps to 30.87% in 2023, then crashed by -91bps to 58.81% in 2024, then soared by 57bps to 25.54% in 2025.
  • Its last three reported values are 25.54% in Q3 2025, 26.31% for Q2 2025, and 40.46% during Q1 2025.